August 23, 2017, San Francisco, Ca., USA - Atara Biotherapeutics, an "off-the-shelf" T-cell immunotherapy company, announced the appointment of Kanya Rajangam as senior vice president and chief medical officer.
Atara Biotherapeutics appoints Kanya Rajangam as CMOStaff Writer | San Francisco, Ca., USA | Wednesday August 23, 2017 6:27AM ET
READ MOREDr. Rajangam joins Atara from Cleave Biosciences where she served as Chief Medical Officer, overseeing clinical development programs in hematologic and solid tumor malignancies.
Previously, Dr. Rajangam was a Senior Medical Director at Onyx Pharmaceuticals, where she played a key role in the successful FDA and EMA submissions of the multiple myeloma product KYPROLIS (carfilzomib).
Prior to this, Dr. Rajangam was Associate Medical Director at Exelixis, where she designed early-stage oncology clinical studies, including for COMETRIQ (cabozantinib) and COTELLIC (cobimetinib).
Throughout her career, Dr. Rajangam has worked closely with pharmaceutical partners including Amgen, Sanofi, Bristol-Myers Squibb and Genentech to advance oncology programs in all phases of clinical development.
After earning her medical degree from St. John’s Medical College in Bangalore, India, she completed a surgical residency, including a master’s thesis in renal transplantation, at the Postgraduate Institute of Medical Education and Research (India).
Dr. Rajangam then earned her doctorate in biomedical tissue engineering from Northwestern University. ■
LATEST MOVES FROM California
- Twitter adds two to board
- Surgical Affiliates appoints Scott Flacks as chief operating officer
- Sangamo Therapeutics appoints Edward Rebar as senior vice president
- Banc of California promotes Jason Pendergist to executive vice president
- Phoenix American Financial Services appoints Robyn Holloway as vice president